Qiong Wu

AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon–Small-Cell Lung Cancer With EGFR Exon 19 Deletion or L858R Mutations

Xiaoping Zhou, V. Miller, Siraj M. Ali, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Next-day manufacture of a novel anti-CD19 CAR-T therapy for B-cell acute lymphoblastic leukemia: first-in-human clinical study

Jiaping He, W. Cao, Wen-Juan Yin, 2022, Blood Cancer Journal.

Efficacy and safety of alfosbuvir plus daclatasvir in Chinese patients with hepatitis C virus genotypes 1, 2, 3, and 6 infection: An open‐label, phase 2 study

Y. Guan, J. Niu, Yongfang Jiang, 2022, Journal of viral hepatitis.

Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B

Peng Hu, J. Niu, Guicheng Wu, 2021, Alimentary pharmacology & therapeutics.

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients

Peng Hu, J. Niu, Guicheng Wu, 2022, Journal of clinical and translational hepatology.

Biosimilarity of HS-20090 to Denosumab in healthy Chinese subjects: a randomized, double-blinded, pharmacokinetics/pharmacodynamics study

Jie Huang, Shuang Yang, Xiao-yan Yang, 2022, Expert opinion on investigational drugs.

Cost-Effectiveness Analysis of Relmacabtagene Autoleucel for Relapsed or Refractory Large B-Cell Lymphoma in China.

Chenyu Zuo, J. Xuan, Ziyi Lin, 2023, Value in health regional issues.

HS‐10352 in hormone receptor‐positive, HER2‐negative advanced breast cancer: A phase 1 dose‐escalation trial

Jian Zhang, Q. Ouyang, Ying Wang, 2023, Cancer medicine.